A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy

Trial Profile

A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs JZP 110 (Primary)
  • Indications Narcolepsy
  • Focus Therapeutic Use
  • Sponsors Aerial BioPharma; Jazz Pharmaceuticals Inc
  • Most Recent Events

    • 02 Jun 2014 Primary endpoint has been met according to a Jazz Pharmaceuticals media release (Evaluate the Clinical Global Impression-Change scores).
    • 02 Jun 2014 Primary endpoint has been met according to a Jazz Pharmaceuticals media release (Evaluate the change from Baseline in the average sleep latency time (in minutes) as determined from the Maintenance of Wakefulness Test).
    • 02 Jun 2014 Results published in a Jazz Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top